A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine

William W. Stoops; Joshua A. Lile; Paul E.A. Glaser; Craig R. Rush

doi:10.1016/j.drugalcdep.2006.02.004

A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine

William W. Stoops, Joshua A. Lile, Paul E.A. Glaser, Craig R. Rush

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

Despite increased reports of amphetamine abuse and dependence, a putative pharmacotherapy has yet to be identified. In a previous study from our laboratory, 20 mg aripiprazole, an atypical antipsychotic that has partial agonist activity at D₂ receptors, attenuated many of the behavioral effects of d-amphetamine. Aripiprazole (20 mg) also impaired performance on a computerized version of the DSST when administered alone, indicating that the attenuation observed may have been functional as opposed to receptor mediated. The present experiment was conducted to determine whether a lower dose of aripiprazole (10 mg) could acutely attenuate the discriminative-stimulus, subject-rated, and physiological effects of d-amphetamine (2.5-15 mg) without impairing performance as measured with a computerized version of the DSST. The results of the present experiment indicate that 10 mg aripiprazole attenuated some abuse-related behavioral effects of d-amphetamine and was generally devoid of effects, including significant performance impairment, when administered alone. These findings suggest that 10 mg aripiprazole would be a reasonable starting dose for the treatment of stimulant abuse and dependence. Future research should examine the effects of chronic aripiprazole administration in combination with methamphetamine or cocaine.

Original language	English
Pages (from-to)	206-209
Number of pages	4
Journal	Drug and Alcohol Dependence
Volume	84
Issue number	2
DOIs	https://doi.org/10.1016/j.drugalcdep.2006.02.004
State	Published - Sep 15 2006

Bibliographical note

Funding Information:
Grants from the National Institute on Drug Abuse (R01 DA 010325, R01 DA 017711, and T32 DA007304) supported this research. This research was conducted in partial fulfillment of William W. Stoops’ doctoral degree in the College of Arts and Sciences at the University of Kentucky. The authors wish to thank Frances Wagner, R.N., for her expert medical assistance and John Blackburn, Michelle Gray, Jamie Haga, Derek Roe, and Andrea Vansickel for their skilled technical assistance.

Funding

Grants from the National Institute on Drug Abuse (R01 DA 010325, R01 DA 017711, and T32 DA007304) supported this research. This research was conducted in partial fulfillment of William W. Stoops’ doctoral degree in the College of Arts and Sciences at the University of Kentucky. The authors wish to thank Frances Wagner, R.N., for her expert medical assistance and John Blackburn, Michelle Gray, Jamie Haga, Derek Roe, and Andrea Vansickel for their skilled technical assistance.

Funders	Funder number
National Institute on Drug Abuse	R01 DA 010325, T32DA007304, R01 DA 017711

Keywords

Aripiprazole
Drug discrimination
Partial agonist
Subject-rated effects
d-Amphetamine

ASJC Scopus subject areas

Toxicology
Pharmacology
Psychiatry and Mental health
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.drugalcdep.2006.02.004

Cite this

@article{a4e6c4f7846d44cc9d724bbba2aa987e,

title = "A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine",

abstract = "Despite increased reports of amphetamine abuse and dependence, a putative pharmacotherapy has yet to be identified. In a previous study from our laboratory, 20 mg aripiprazole, an atypical antipsychotic that has partial agonist activity at D2 receptors, attenuated many of the behavioral effects of d-amphetamine. Aripiprazole (20 mg) also impaired performance on a computerized version of the DSST when administered alone, indicating that the attenuation observed may have been functional as opposed to receptor mediated. The present experiment was conducted to determine whether a lower dose of aripiprazole (10 mg) could acutely attenuate the discriminative-stimulus, subject-rated, and physiological effects of d-amphetamine (2.5-15 mg) without impairing performance as measured with a computerized version of the DSST. The results of the present experiment indicate that 10 mg aripiprazole attenuated some abuse-related behavioral effects of d-amphetamine and was generally devoid of effects, including significant performance impairment, when administered alone. These findings suggest that 10 mg aripiprazole would be a reasonable starting dose for the treatment of stimulant abuse and dependence. Future research should examine the effects of chronic aripiprazole administration in combination with methamphetamine or cocaine.",

keywords = "Aripiprazole, Drug discrimination, Partial agonist, Subject-rated effects, d-Amphetamine",

author = "Stoops, {William W.} and Lile, {Joshua A.} and Glaser, {Paul E.A.} and Rush, {Craig R.}",

note = "Funding Information: Grants from the National Institute on Drug Abuse (R01 DA 010325, R01 DA 017711, and T32 DA007304) supported this research. This research was conducted in partial fulfillment of William W. Stoops{\textquoteright} doctoral degree in the College of Arts and Sciences at the University of Kentucky. The authors wish to thank Frances Wagner, R.N., for her expert medical assistance and John Blackburn, Michelle Gray, Jamie Haga, Derek Roe, and Andrea Vansickel for their skilled technical assistance.",

year = "2006",

month = sep,

day = "15",

doi = "10.1016/j.drugalcdep.2006.02.004",

language = "English",

volume = "84",

pages = "206--209",

number = "2",

}

TY - JOUR

T1 - A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine

AU - Stoops, William W.

AU - Lile, Joshua A.

AU - Glaser, Paul E.A.

AU - Rush, Craig R.

N1 - Funding Information: Grants from the National Institute on Drug Abuse (R01 DA 010325, R01 DA 017711, and T32 DA007304) supported this research. This research was conducted in partial fulfillment of William W. Stoops’ doctoral degree in the College of Arts and Sciences at the University of Kentucky. The authors wish to thank Frances Wagner, R.N., for her expert medical assistance and John Blackburn, Michelle Gray, Jamie Haga, Derek Roe, and Andrea Vansickel for their skilled technical assistance.

PY - 2006/9/15

Y1 - 2006/9/15

N2 - Despite increased reports of amphetamine abuse and dependence, a putative pharmacotherapy has yet to be identified. In a previous study from our laboratory, 20 mg aripiprazole, an atypical antipsychotic that has partial agonist activity at D2 receptors, attenuated many of the behavioral effects of d-amphetamine. Aripiprazole (20 mg) also impaired performance on a computerized version of the DSST when administered alone, indicating that the attenuation observed may have been functional as opposed to receptor mediated. The present experiment was conducted to determine whether a lower dose of aripiprazole (10 mg) could acutely attenuate the discriminative-stimulus, subject-rated, and physiological effects of d-amphetamine (2.5-15 mg) without impairing performance as measured with a computerized version of the DSST. The results of the present experiment indicate that 10 mg aripiprazole attenuated some abuse-related behavioral effects of d-amphetamine and was generally devoid of effects, including significant performance impairment, when administered alone. These findings suggest that 10 mg aripiprazole would be a reasonable starting dose for the treatment of stimulant abuse and dependence. Future research should examine the effects of chronic aripiprazole administration in combination with methamphetamine or cocaine.

AB - Despite increased reports of amphetamine abuse and dependence, a putative pharmacotherapy has yet to be identified. In a previous study from our laboratory, 20 mg aripiprazole, an atypical antipsychotic that has partial agonist activity at D2 receptors, attenuated many of the behavioral effects of d-amphetamine. Aripiprazole (20 mg) also impaired performance on a computerized version of the DSST when administered alone, indicating that the attenuation observed may have been functional as opposed to receptor mediated. The present experiment was conducted to determine whether a lower dose of aripiprazole (10 mg) could acutely attenuate the discriminative-stimulus, subject-rated, and physiological effects of d-amphetamine (2.5-15 mg) without impairing performance as measured with a computerized version of the DSST. The results of the present experiment indicate that 10 mg aripiprazole attenuated some abuse-related behavioral effects of d-amphetamine and was generally devoid of effects, including significant performance impairment, when administered alone. These findings suggest that 10 mg aripiprazole would be a reasonable starting dose for the treatment of stimulant abuse and dependence. Future research should examine the effects of chronic aripiprazole administration in combination with methamphetamine or cocaine.

KW - Aripiprazole

KW - Drug discrimination

KW - Partial agonist

KW - Subject-rated effects

KW - d-Amphetamine

UR - http://www.scopus.com/inward/record.url?scp=33746324268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746324268&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2006.02.004

DO - 10.1016/j.drugalcdep.2006.02.004

M3 - Article

C2 - 16540264

AN - SCOPUS:33746324268

SN - 0376-8716

VL - 84

SP - 206

EP - 209

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

IS - 2

ER -

A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this